Entry Point Capital, LLC 4 D Molecular Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 24,519 shares of FDMT stock, worth $161,825. This represents 0.15% of its overall portfolio holdings.
Number of Shares
24,519
Previous 7,265
237.49%
Holding current value
$161,825
Previous $152 Million
99.83%
% of portfolio
0.15%
Previous 0.22%
Shares
2 transactions
Others Institutions Holding FDMT
# of Institutions
146Shares Held
57.1MCall Options Held
137KPut Options Held
111K-
Bvf Inc San Francisco, CA7.38MShares$48.7 Million2.54% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.1MShares$33.6 Million0.77% of portfolio
-
Black Rock Inc. New York, NY4.9MShares$32.3 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.4MShares$29 Million4.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.1MShares$27 Million1.63% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $214M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...